Evidence map›Paper›PMID 39985032›Full record

ArticleCancer cell international2025

Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression.

Joseph Lin, Yueh-Te Lin, Kai-Wen Hsu, Yi-En Liu, Yun-Cen Chen, Yung-Liang Yeh, Hsin-Ya Huang, Chang-Chi Hsieh, Dar-Ren Chen, Han-Tsang Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joseph Lin *Cancer Research Center, Changhua Christian Hospital, Changhua, 500, Taiwan, R.O.C.
Yueh-Te Lin *Cancer Genome Research Center, Department of Medical Research and Development, Chang Gung Memorial Hospital at Linkou, Taoyuan, 333, Taiwan, R.O.C.
Kai-Wen Hsu *Research Center for Cancer Biology, Institute of New Drug Development, China Medical University, Taichung, 404, Taiwan, R.O.C.
Yi-En LiuCancer Research Center, Changhua Christian Hospital, Changhua, 500, Taiwan, R.O.C.
Yun-Cen ChenCancer Research Center, Changhua Christian Hospital, Changhua, 500, Taiwan, R.O.C.
Yung-Liang YehComprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua, 500, Taiwan, R.O.C.
Hsin-Ya HuangComprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua, 500, Taiwan, R.O.C.
Chang-Chi HsiehDepartment of Animal Science and Biotechnology, Tunghai University, Taichung, 407, Taiwan, R.O.C.
Dar-Ren ChenCancer Research Center, Changhua Christian Hospital, Changhua, 500, Taiwan, R.O.C.. drchen.cch@gmail.com.
Han-Tsang WuCancer Research Center, Changhua Christian Hospital, Changhua, 500, Taiwan, R.O.C.. 182033@cch.org.tw.

Funding

Chang Gung Memorial Hospital, Linkou CMRPG3M1841Changhua Christian Hospital 112-CCH-IRP-090China Medical University, Taiwan CMU112-MF-06Ministry of Education the "Drug Development Center, China Medical University" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout ProjectMinistry of Science and Technology, Taiwan MOST-110-2314-B-371-007-MY3Ministry of Science and Technology, Taiwan MOST 111-2628-B-039-007-MY3
6 · The paper itself

Abstract

Estrogen receptor-positive breast cancer (ERPBC) accounts for approximately 70% of breast cancers in women worldwide. The therapeutic strategy process for ERPBC is well-established and significantly reduces the mortality rate. The discovery of new therapeutic targets remains essential for ERPBC patients with metastasis or endocrine resistance. This study indicated that USP7 is highly expressed in ERBPC and promotes tumor progression and metastasis. Inhibition of USP7 activity repressed proliferation, induced apoptosis, suppressed migration and invasive activities, and reversed the epithelial-mesenchymal transition of ERPBC. Mass spectrometry analysis indicated that USP7 regulates CDK1 expression, which is highly expressed and correlates with a poor overall survival rate in ERPBC. USP7 directly interacts with CDK1 and regulates its stability. The combined inhibition of USP7 and CDK1 by GNE-6776 and Ro-3306 synergistically represses the malignant process and metastasis of ERPBC. These findings proved that targeting USP7 and CDK1 is a potential strategy for overcoming endocrine resistance in patients with advanced ERPBC.

Indexed as

CDK1DeubiquitinationEstrogen receptor-positive breast cancerTumor progressionUSP7

Identifiers

PMID39985032
PMCPMC11846418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.